Helen M. Thackray net worth and biography

Helen Thackray Biography and Net Worth

Chief Research & Development Officer of BioCryst Pharmaceuticals

Dr. Thackray is the Chief Research and Development Officer for BioCryst. Prior to joining the company, she was the Chief Medical Officer and Senior Vice President of Clinical Development at GlycoMimetics, Inc., where she led their orphan product, fast-track, and breakthrough therapy programs in rare diseases and oncology. Previous experience includes a senior role in clinical development at Biosynexus, and over a decade on the Research Ethics Review Board of the National Center for Healthcare Statistics, part of the Centers for Disease Control and Prevention. She is a board-certified pediatrician, serving on the faculty of the Children’s National Medical Center and George Washington University School of Medicine and Health Sciences from 2000 to present. Dr. Thackray holds a B.S. in Biological Sciences from Stanford University, an M.D. from the George Washington University School of Medicine and Health Sciences, and has authored more than 60 peer-reviewed articles and presentations. She completed her pediatric residency and chief residency at Children’s National Medical Center, trained in medical genetics at the National Human Genome Research Institute at the National Institutes of Health, and is a fellow of the American Academy of Pediatrics.

What is Helen M. Thackray's net worth?: The estimated net worth of Helen M. Thackray is at least $2.02 million as of May 14th, 2024. Dr. Thackray owns 272,139 shares of BioCryst Pharmaceuticals stock worth more than $2,021,993 as of April 3rd. This net worth estimate does not reflect any other assets that Dr. Thackray may own. Learn More about Helen M. Thackray's net worth.
How do I contact Helen M. Thackray?: The corporate mailing address for Dr. Thackray and other BioCryst Pharmaceuticals executives is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. BioCryst Pharmaceuticals can also be reached via phone at (919) 859-1302 and via email at investorrelations@biocryst.com. Learn More on Helen M. Thackray's contact information.
Has Helen M. Thackray been buying or selling shares of BioCryst Pharmaceuticals?: Helen M. Thackray has not been actively trading shares of BioCryst Pharmaceuticals during the last quarter. Most recently, on Tuesday, May 14th, Helen M. Thackray bought 30,000 shares of BioCryst Pharmaceuticals stock. The stock was acquired at an average cost of $5.86 per share, with a total value of $175,800.00. Following the completion of the transaction, the insider now directly owns 272,139 shares of the company's stock, valued at $1,594,734.54. Learn More on Helen M. Thackray's trading history.
Who are BioCryst Pharmaceuticals' active insiders?: BioCryst Pharmaceuticals' insider roster includes George Abercrombie (Director), Steve Aselage (Director), Yarlagadda Babu (Insider), Alane Barnes (Insider), Anthony Doyle (CFO), Steven Galson (Director), Nancy Hutson (Director), Alan Levin (Director), Amy McKee (Director), Vincent Milano (Director), Machelle Sanders (Director), William Sheridan (Insider), Jon Stonehouse (CEO), and Helen Thackray (Chief Research & Development Officer). Learn More on BioCryst Pharmaceuticals' active insiders.
Are insiders buying or selling shares of BioCryst Pharmaceuticals?: During the last twelve months, BioCryst Pharmaceuticals insiders bought shares 6 times. They purchased a total of 103,601 shares worth more than $596,337.56. During the last twelve months, insiders at the biotechnology company sold shares 2 times. They sold a total of 13,289 shares worth more than $82,486.00. The most recent insider tranaction occured on June, 24th when Director Amy E Mckee sold 8,600 shares worth more than $54,352.00. Insiders at BioCryst Pharmaceuticals own 4.8% of the company. Learn More about insider trades at BioCryst Pharmaceuticals.
Information on this page was last updated on 6/24/2024.

Helen M. Thackray Insider Trading History at BioCryst Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/14/2024	Buy	30,000	$5.86	$175,800.00	272,139
12/15/2022	Sell	3,125	$10.89	$34,031.25	133,275
4/1/2022	Sell	7,600	$16.20	$123,120.00	136,400

Helen M. Thackray Buying and Selling Activity at BioCryst Pharmaceuticals

BioCryst Pharmaceuticals Company Overview

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Today's Range

Now: $7.43

$7.15

$7.44

50 Day Range

MA: $8.17

$7.25

$9.39

2 Week Range

Now: $7.43

$4.03

$9.50

Volume

2,223,517 shs

Average Volume

2,760,443 shs

Market Capitalization

$1.55 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.84